Coronavirus Update: After 'Warp Speed' Snub, Novavax Awarded US Military Vaccine Deal
Plus: Inovio Launches First South Korea Vaccine Study
Executive Summary
Progress for two US-based companies in the race to develop a COVID-19 vaccine.
You may also be interested in...
Reference Pricing Clauses In US COVID-19 Contracts Leave Drug Industry Vulnerable
Innovation and price controls can coexist in the United States, COVID-19 contracts show. But drug pricing experts also acknowledge the unique circumstances of COVID-19 could make such contracts hard to replicate and argue that reference-pricing strategies may have limited ability to lower prices.
Finance Watch: 14 Biopharma IPOs In One Remarkable Month
Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.
Coronavirus Update: COVID-19 Funding Crisis For UK Medical Charities, Inovio Gets US Government Cash
UK medical research charities call for government assistance to temper damage caused by the pandemic, Inovio gets $71m in DOD contract to fund its vaccine, while ViralClear partners with Catalent to produce oral formulations of its antiviral merimepodib.